Cellectis S.A. ADR (CLLS) Stock Price, Quote & News

Company Profile

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence,...

Industry: Biotechnology

Sector: Healthcare

Phone: 33 1 81 69 16 00

Website: www.cellectis.com

Address:

8, rue de la Croix Jarry, Paris, France

rlkloehn Apr. 23 at 3:08 AM

$CLLS quite the video https://www.linkedin.com/posts/cellectis_car-t-cells-killing-cancer-cells-activity-7452721909844189184-COYR

0 · Reply

PennyScam Apr. 18 at 10:20 PM

$CLLS Great stuff. On the rise. Nice. Crazy K

0 · Reply

OfficialStocktwitsUser Apr. 17 at 8:29 PM

$CLLS RSI: 83.84, MACD: 0.1747 Vol: 0.43, MA20: 3.57, MA50: 3.66 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

PSM_EmpowerTrading Apr. 13 at 1:22 PM

🌅 Watchlist part 2 ✅ $BATL low 4 support, if above 4.20, have potential to 4.50/4.60 ✅ $DEVS .70 support, if above .85, have potential to 1/1.50 ✅ $ATCH low .20 support, if above .30, have potential to .40/.50 ✅ $CLLS low 4 support, still low volume, if above 4.50, have potential to 4.75/5 ✅ $TMDE 1.40 support, if above 1.65, have potential to 1.80/2 🚨 The above tickers are not ideal for swing accumulation at current price 🚨 ✅ Ideal long entry near low current support 🎯 Ideal stop loss if below current support 🚨 Avoid chasing long into strength near resistance 🎯🎯 Goal is GREEN 🤑🤑 not GREED 🥵🥵

0 · Reply

vcaelum Apr. 13 at 12:33 PM

$CLLS lets go 5+ dont hhit my $4 SL pls

0 · Reply

vcaelum Apr. 13 at 12:27 PM

$CLLS was there any updates or something that i missed? got in 4.6. HARD SL at 4, looking for 5+

0 · Reply

Stock_Catcher Apr. 13 at 12:11 PM

$CLLS Thin one

0 · Reply

PennyScam Apr. 11 at 4:07 PM

$CLLS Thanks RK. I’m a fan like you. Best to you. Crazy K

0 · Reply

rlkloehn Apr. 10 at 8:25 PM

$CLLS Box 1: Three questions to André Choulika, co-founder and CEO of Cellectis. Pharma Industry: How does your approach to CAR-T differ from current therapies? André Choulika: Cellectis is a biotech specialized in genome editing, which aims to develop so-called allogeneic CAR-Ts, to fight cancer. T cells, which we therefore take from healthy donors, are genetically modified via our TALEN technology, "molecular scissors" that activate, inactivate or replace certain genes. Thanks to this platform, we can program the cells to become real living drugs. These cells are then frozen and ready to use, available immediately, as soon as a patient needs them. In the long run, we want to extend our platform to broader applications, particularly in immunology and against rare genetic diseases. Production is often presented as the main challenge of CAR-T. How did you approach this issue?

1 · Reply

StocktwitsEarnings Mar. 20 at 11:57 AM

$CLLS Q4 '25 Earnings Results & Recap Cellectis anticipates continued significant expenses and operating losses for the foreseeable future, requiring additional funding that may not be available on acceptable terms or at all.

0 · Reply

Market Cap	392.33M
Revenue (ttm)	79.59M
Net Income (ttm)	-67.59M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-84.92%
Debt to Equity Ratio	1.11

Volume	12,100
Avg Vol	44,548
Day's Range	N/A - N/A
Shares Out	100.34M
Stochastic %K	10%
Beta	2.91
Analysts	Strong Sell
Price Target	$7.25